All Stories

  1. Intramuscular Cyanocobalamin Treatment in Patients with Corpus Atrophic Gastritis and Vitamin B12 Deficiency: Efficacy and Predictors of Increased Requirement—A Monocentric Longitudinal Real-Life Cohort Study
  2. Helicobacter pylori multiplex serology in patients with autoimmune atrophic gastritis negative for Helicobacter pylori at histology: A case-control study
  3. Endoscopic follow-up in patients with first-degree relatives for gastric cancer: a real-world observational study
  4. Autoimmune gastritis: Diagnosis, clinical management and natural history. A position paper by the Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)
  5. The indolent nature of type 1 gastric neuroendocrine tumors under 1 cm
  6. Chronic atrophic gastritis and dyspepsia: a forgotten link?
  7. Letter to the Editor
  8. Bile acid diarrhea in patients with chronic diarrhea. Current appraisal and recommendations for clinical practice
  9. Antral mucosa healing at long-term follow-up in patients with corpus atrophic gastritis and concomitant antral gastritis may mimic autoimmune gastritis
  10. Look inside the management of colonic diverticular rebleeding: a systematic review
  11. The Diagnosis and Management of Chronic Constipation in Italy: Results from a Survey Conducted among Italian Gastroenterologists
  12. Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
  13. Sarcopenia in Patients with Advanced Gastrointestinal Well-Differentiated Neuroendocrine Tumors
  14. Symptomatic uncomplicated diverticular disease: a critical appraisal
  15. Convolutional Neural Network Model for Intestinal Metaplasia Recognition in Gastric Corpus Using Endoscopic Image Patches
  16. Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?
  17. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis – Definition, Clinical Presentation and Diagnosis
  18. Clinical Outcome of Patients with Gastric, Duodenal, or Rectal Neuroendocrine Tumors after Incomplete Endoscopic Resection
  19. Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
  20. Endoscopic management of gastric, duodenal and rectal NETs: Position paper from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Society of Gastroenterology (SIGE), Italian Society of Digestive Endoscopy (SIED)
  21. Systematic review and meta‐analysis: Risk of gastric cancer in patients with first‐degree relatives with gastric cancer
  22. Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study
  23. Common Diagnostic Challenges and Pitfalls in Segmental Colitis Associated with Diverticulosis (SCAD)
  24. Gastric Microbiota Gender Differences in Subjects with Healthy Stomachs and Autoimmune Atrophic Gastritis
  25. Comparison of Clinical, Biochemical and Histological Features between Adult Celiac Patients with High and Low Anti-Transglutaminase IgA Titer at Diagnosis and Follow-Up
  26. Patients with Diverticular Disease Have Different Dietary Habits Compared to Control Subjects: Results from an Observational Italian Study
  27. Sex–Gender Differences in Adult Coeliac Disease at Diagnosis and Gluten-Free-Diet Follow-Up
  28. Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia: A Case Series
  29. Prevalence of Segmental Colitis Associated with Colonic Diverticulosis in a Prospective Cohort of Patients Who Underwent Colonoscopy in a Tertiary Center
  30. Editorial: lymphocytic gastritis and its relationships with other gastrointestinal disorders
  31. Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics
  32. Role of Dietary Habits in the Prevention of Diverticular Disease Complications: A Systematic Review
  33. Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia: A Systematic Review
  34. Gastrectomy for stage IV gastric cancer: a comparison of different treatment strategies from the SEER database
  35. Diagnostic Accuracy of EndoFaster® and Narrow-Band Imaging Endoscopy in Patients with Impaired Gastric Acid Secretion: A Real-Time Prospective Study
  36. Relationship between Persistent Gastrointestinal Symptoms and Duodenal Histological Findings after Adequate Gluten-Free Diet: A Gray Area of Celiac Disease Management in Adult Patients
  37. Common Pitfalls in the Management of Patients with Micronutrient Deficiency: Keep in Mind the Stomach
  38. Autoimmune Gastritis and Gastric Microbiota
  39. Prevalence of Sars-Cov-2 Infection in Health Workers (HWs) and Diagnostic Test Performance: The Experience of a Teaching Hospital in Central Italy
  40. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs
  41. SARS-CoV2 RNA detection in a pancreatic pseudocyst sample
  42. The Trends of Complicated Acute Colonic Diverticulitis—A Systematic Review of the National Administrative Databases
  43. Cell Blood Count Alterations and Patterns of Anaemia in Autoimmune Atrophic Gastritis at Diagnosis: A Multicentre Study
  44. Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian...
  45. Occurrence of Acute Oesophageal Necrosis (Black Oesophagus) in a Single Tertiary Centre
  46. Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
  47. Do Alterations in Bone Mineral Density Go Beyond Borders in Adults With Celiac Disease?
  48. Multidisciplinary Management of Neuroendocrine Neoplasia: A Real-World Experience from a Referral Center
  49. A single vial is enough in the absence of endoscopic suspected intestinal metaplasia – less is more!
  50. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study
  51. Treatment of diverticular disease, targeting symptoms or underlying mechanisms
  52. Risk Factors Associated with the Occurrence of Autoimmune Diseases in Adult Coeliac Patients
  53. Recent advances in understanding and managing diverticulitis
  54. Demographic and clinical features distinguish subgroups of diverticular disease patients: Results from an Italian nationwide registry
  55. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE)
  56. Diverticular disease: myths and facts
  57. Cost of detecting gastric neoplasia by surveillance endoscopy in atrophic gastritis in Italy: A low risk country
  58. Role of Fiber in Symptomatic Uncomplicated Diverticular Disease: A Systematic Review
  59. Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients
  60. Upper gastrointestinal symptoms in autoimmune gastritis
  61. Time trend occurrence of duodenal intraepithelial lymphocytosis and celiac disease in an open access endoscopic population
  62. Role of endoscopic surveillance for intestinal metaplasia limited to the antrum
  63. Italian Guidelines
  64. Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate
  65. Gastric precancerous conditions andHelicobacter pyloriinfection in dyspeptic patients with or without endoscopic lesions
  66. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions
  67. Letter: gastric cancer and pernicious anaemia - only a minority of UK pernicious anaemia patients have had a gastroscopy - authors’ reply
  68. A case of Barrett’s oesophagus in pernicious anaemia: acid is not the only culprit!
  69. Pernicious Anemia: Time to Justify Endoscopic Monitoring?
  70. Endoscopic appearances of polypoid type 1 gastric microcarcinoids by narrow-band imaging
  71. Probiotics and Diverticular Disease
  72. Symbiotics, Probiotics, and Fiber Diet in Diverticular Disease
  73. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015
  74. ATPase4A Autoreactivity and Its Association With Autoimmune Phenotypes in the Type 1 Diabetes Genetics Consortium Study
  75. Practice parameters for the treatment of colonic diverticular disease: Italian Society of Colon and Rectal Surgery (SICCR) guidelines
  76. Prevalence and distribution of colonic diverticula assessed with CT colonography (CTC)
  77. Single nucleotide polymorphisms related to vitamin B12 serum levels in autoimmune gastritis patients with or without pernicious anaemia
  78. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up
  79. E-cadherin germline mutation carriers: clinical management and genetic implications
  80. Updated features associated with type 1 gastric carcinoids patients: a single-center study
  81. Editorial: mucosal healing and adherence to the gluten-free diet in coeliac disease - authors' reply
  82. Prevalence of lesions detected at upper endoscopy: An Italian survey
  83. Detection of Gastric Precancerous Conditions in Daily Clinical Practice: A Nationwide Survey
  84. Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study
  85. Italian consensus conference for colonic diverticulosis and diverticular disease
  86. Histological recovery and gluten-free diet adherence: a prospective 1-year follow-up study of adult patients with coeliac disease
  87. Gastric cancer in patients with type I gastric carcinoids
  88. Are clinical features able to predict Helicobacter pylori gastritis patterns? Evidence from tertiary centers
  89. Proton pump inhibitor therapy and potential long-term harm
  90. Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge
  91. Helicobacter pyloriinfection and drugs malabsorption
  92. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome
  93. A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders
  94. Letter: gastric cancer and pernicious anaemia - oftenHelicobacter pyloriin disguise; authors' reply
  95. Intestinal metaplasia surveillance: Searching for the road-map
  96. Systematic review: gastric cancer incidence in pernicious anaemia
  97. No higher risk for colorectal cancer in atrophic gastritis-related hypergastrinemia
  98. Appropriateness of the Indication for Colonoscopy
  99. Chronic Idiophatic Urticaria and Helicobacter Pylori: A Specific Pattern of Gastritis and Urticaria Remission after Helicobacter Pylori Eradication
  100. Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey
  101. Micronutrients (Other than iron) and Helicobacter pylori Infection: A Systematic Review
  102. High-fibre diet andLactobacillus paracasei B21060in symptomatic uncomplicated diverticular disease
  103. Is proliferative colonic disease presentation changing?
  104. Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal
  105. Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate
  106. Role of gastritis pattern on Helicobacter pylori eradication
  107. Treatment of Diverticular Disease of the Colon and Prevention of Acute Diverticulitis: A Systematic Review
  108. Diagnosis and Management of Pernicious Anemia
  109. Development of type I gastric carcinoid in patients with chronic atrophic gastritis
  110. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up
  111. Immunoproteomics of Helicobacter pylori infection in patients with atrophic body gastritis, a predisposing condition for gastric cancer
  112. HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population
  113. Low prevalence of idiopathic peptic ulcer disease: An Italian endoscopic survey
  114. Cost-effectiveness of Endoscopic Surveillance for Gastric Intestinal Metaplasia
  115. Helicobacter pyloriimmunoproteomics in gastric cancer and gastritis of the carcinoma phenotype
  116. Appropriateness of the indication for upper endoscopy: A meta-analysis
  117. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis
  118. Systematic review: distribution of advanced neoplasia according to polyp size at screening colonoscopy
  119. High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis
  120. Reassessment of Intrinsic Factor and Parietal Cell Autoantibodies in Atrophic Gastritis With Respect to Cobalamin Deficiency
  121. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy
  122. Systematic review:Heliocobacter pyloriinfection and impaired drug absorption
  123. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
  124. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy
  125. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
  126. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography
  127. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation
  128. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs
  129. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors
  130. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations
  131. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide
  132. Pernicious anemia: New insights from a gastroenterological point of view
  133. Pre-endoscopic screening for Helicobacter pylori and celiac disease in young anemic women
  134. Benefit of concomitant gastrointestinal and gynaecological evaluation in premenopausal women with iron deficiency anaemia
  135. A Prospective Study of Gastric Carcinoids and Enterochromaffin-Like Cell Changes in Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Identification of Risk Factors
  136. The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI)
  137. Occurrence and Risk Factors for Autoimmune Thyroid Disease in Patients with Atrophic Body Gastritis
  138. Artificial neural networks in the recognition of the presence of thyroid disease in patients with atrophic body gastritis
  139. Assessing the severity of atrophic gastritis
  140. Is interleukin-1 genotyping useful for the clinical management of patients with atrophic body gastritis?
  141. After Helicobacter pylori, Genetic Susceptibility to Gastric Carcinoma Revisited
  142. Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger-Ellison syndrome and antral G-cell hyperfunction
  143. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease
  144. Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients
  145. Omeprazole versus famotidine in the short-term treatment of duodenal ulcer disease
  146. CagA and VacA are Immunoblot Markers of Past Helicobacter pylori Infection in Atrophic Body Gastritis
  147. Corpus-predominant gastritis as a risk factor for false-negative13C-urea breath test results
  148. Thyroxine in Goiter, H. pylori Infection, and Gastritis
  149. Thyroxine in Goiter,Helicobacter pyloriInfection, and Chronic Gastritis
  150. Unawareness of gastrointestinal symptomatology in adult coeliac patients with unexplained iron-deficiency anaemia presentation
  151. Western Blotting of Total Lysate of Helicobacter pylori in Cases of Atrophic Body Gastritis
  152. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection
  153. Of Bacteria, Acid, and Blood
  154. Occurrence and risk factors for benign epithelial gastric polyps in atrophic body gastritis on diagnosis and follow-up
  155. Early Manifestations of Gastric Autoimmunity in Patients with Juvenile Autoimmune Thyroid Diseases
  156. Role of Noninvasive Tests (13C-Urea Breath Test and Stool Antigen Test) as Additional Tools in Diagnosis ofHelicobacter PyloriInfection in Patients with Atrophic Body Gastritis
  157. Can patient characteristics predict the outcome of endoscopic evaluation of iron deficiency anemia: a multiple logistic regression analysis
  158. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment
  159. Gastric Neuroendocrine Tumors
  160. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors
  161. Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy
  162. IS ENDOSCOPY WORTHWHILE IN MENSTRUATING FEMALES WITH IRON DEFICIENCY?
  163. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract
  164. DXA vs. QCT for subclinical celiac disease patients
  165. Intragastric Ascorbic But Not Uric Acid is Depleted in Relation with the Increased pH in Patients with Atrophic Body Gastritis and H. Pylori Gastritis
  166. Co-existence of hyperparathyroidism, hypergastrinaemia and multiple gastric carcinoids is not always due to incomplete expression of the MEN-1 syndrome
  167. Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia
  168. The stomach and iron deficiency anaemia: a forgotten link
  169. Antibiotic Prophylaxis of Bacterial Infections in Cirrhotic Inpatients: a Meta-Analysis of Randomized Controlled Trials
  170. Timing and sampling in surveillance of premalignant gastric lesions
  171. The long-term effects of cure of Helicobacter pylori infection on patients with atrophic body gastritis
  172. Consequences of Helicobacter pylori infection on the absorption of micronutrients
  173. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas
  174. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients
  175. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment
  176. Iron Deficiency Anaemia Caused by Nonspecific (Idiopathic) Small Bowel Ulceration: An Uncommon Presentation of an Uncommon Disease
  177. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid
  178. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection
  179. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?
  180. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms
  181. Two-thirds of Atrophic Body Gastritis Patients Have Evidence of Helicobacter pylori Infection
  182. Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection
  183. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: When should it be done?
  184. Efficacy of gluten-free diet alone on recovery from iron deficiency anemia in adult celiac patients
  185. Iron deficiency anaemia and Helicobacter pylori infection
  186. Role of Helicobacter pylori infection in pernicious anaemia
  187. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia
  188. Long-term octreotide treatment of metastatic carcinoid tumor
  189. Duodenal Ulcer Relapse Is Not Always Associated with Recurrence of H. pylori Infection: A Prospective Three-Year Follow-Up Study
  190. Prevalence and Causes of Hypergastrinemia in Primary Hyperparathyroidism: A Prospective Study
  191. Correspondence
  192. Atrophic Body Gastritis in Patients With Autoimmune Thyroid Disease
  193. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia A prospective screening study
  194. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases
  195. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours
  196. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs
  197. Atrophic Body Gastritis: Distinct Features Associated with Helicobacter pylori Infection
  198. Reversal of Long-Standing Iron Deficiency Anaemia after Eradication ofHelicobacter pyloriInfection
  199. Absorption of the oral iron preparation ferrous acetyl transferrin in achlorhydric patients: a pilot study
  200. Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia
  201. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth
  202. Somatostatin Receptor Localization of Pancreatic Endocrine Tumors
  203. Modulation of Growth of Human Gastric Enterochromaffin-Like Cells
  204. Effects of Recent, Short-Term Hyperglycemia on Responses to Hypoglycemia in Humans: Relevance to the Pathogenesis of Hypoglycemia Unawareness and Hyperglycemia-Induced Insulin Resistance
  205. Erratum
  206. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM
  207. Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans
  208. Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin a production by intestinal lamina propria lymphocytes
  209. Helicobacter pylori Infection in Children with Antral Gastrin Cell Hyperfunction
  210. Inhibitory effect of somatostatin-14 and some analogues on human natural killer cell activity
  211. Meticulous Prevention of Hypoglycemia Normalizes the Glycemic Thresholds and Magnitude of Most of Neuroendocrine Responses to, Symptoms of, and Cognitive Function During Hypoglycemia in Intensively Treated Patients With Short-Term IDDM
  212. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide
  213. Maintenance Treatment with H2 Receptor Antagonists for Duodenal Ulcer Disease: Toward a Rational Use
  214. Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger?Ellison syndrome during omeprazole treatment
  215. Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity
  216. Gut neuropeptides and the immune system
  217. Effects of somatostatin on human intestinal lamina propria lymphocytes. Modulation of lymphocyte activation
  218. Neurohumoral control of gallbladder motility in healthy subjects and diabetic patients with or without autonomic neuropathy
  219. Effect of Vasoactive Intestinal Peptide Neuropeptide on Natural Killer Activity from Peripheral Blood Lymphocytes of Normal Subjects
  220. Effects of high in vivo levels of vasoactive intestinal polypeptide on function of circulating lymphocytes in humans
  221. Modulatory Effects of Somatostatin and Vasoactive Intestinal Peptide on Human Intestinal Lymphocytes
  222. Medical Treatment of Antral Gastrin Cell Hyperfunction: Role of Nonantisecretory Therapy
  223. Somatostatin Infused during Acute Pancreatitis Retains Its Biological Activity
  224. Loss of Efficacy of Famotidine in the Control of Gastric Acid Secretion in Patients with Zollinger-Ellison Syndrome Reversed by Omeprazole
  225. HYPERGASTRINAEMIA AFTER LONG-TERM H2-BLOCKER TREATMENT
  226. Pancreatic polypeptide response to a protein-rich meal in diabetic patients with and without neuropathy
  227. Gastric acid and pancreatic polypeptide responses to modified sham feeding: indication of an increased basal vagal tone in a subgroup of duodenal ulcer patients.
  228. Evidence that bombesin releases extragastric gastrin in man
  229. Bombesin effects on human GI functions
  230. Peptides of the APUD system in amphibian skins
  231. Bombesin, Trypsin, and Chronic Pancreatitis
  232. Effect of Bombesin on Plasma Insulin, Pancreatic Glucagon, and Gut Glucagon in Man*
  233. NEUROTENSIN AND THE DUMPING SYNDROME